Cibler la voie métabolique du cortisol comme action thérapeutique dans le diabète de type 2

[en] The 11ß-hydroxysteroid dehydrogenase type 1 (11βHSD1) enzyme promotes the local conversion from inactive cortisone to active cortisol. It may play a role in the pathophysiology of abdominal obesity and the metabolic syndrome, both showing some similarities with the Cushing syndrome. Synthetic selective inhibitors of 11βHSD1 have been investigated in pilot studies in overweight/obese patients with type 2 diabetes or hypertension. Although some positive effects were observed, they were considered as too modest compared to what could be obtained with other available drugs. More recently, a reduction in liver steatosis was reported in overweight/obese non-diabetic patients. Whereas some early 11βHSD1 inhibitors have been abandoned, others are still in development, which demonstrates a persisting interest for this innovative therapeutic approach. © 2016 Elsevier Masson SAS

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Title :

Cibler la voie métabolique du cortisol comme action thérapeutique dans le diabète de type 2

Alternative titles :

[en] Targeting the metabolic pathway of cortisol as a potential therapy of type 2 diabetes

Publication date :

2016

Journal title :

Médecine des Maladies Métaboliques

ISSN :

1957-2557

eISSN :

2214-8477

Publisher :

Elsevier Masson SAS

Volume :

Issue :

Pages :

725-731

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 16 November 2017

Statistics

Number of views

65 (1 by ULiège)

Number of downloads

467 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

[1] Anagnostis, P., Athyros, V.G., Tziomalos, K., et al. Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 94 (2009), 2692–2701.
[2] Tomlinson, J.W., Walker, E.A., Bujalska, I.J., et al. 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25 (2004), 831–866.
[3] Gathercole, L.L., Lavery, G.G., Morgan, S.A., et al. 11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. Endocr Rev 34 (2013), 525–555.
[4] Morton, N.M., Obesity and corticosteroids: 11β-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol 316 (2010), 154–164.
[5] Hollis, G., Huber, R., 11β-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus. Diabetes Obes Metab 13 (2011), 1–6.
[6] lovino, A., Scheen, A.J., La 11β-hydroxystéroide déshydrogénase de type 1-1re partie : rôle de l'exposition tissulaire au cortisol dans le risque métabolique lié à l'obésité. Médecine des maladadies Métaboliques 3 (2009), 507–513.
[7] lovino, A., Scheen, A.J., La 11β-hydroxystéroïde déshydrogénase de type 1-2e partie : Inhibition sélective pour traiter les anomalies métaboliques associées à l'obésité. Médecine des maladies Métaboliques 3 (2009), 595–600.
[8] Woods, C., Tomlinson, J.W., The dehydrogenase hypothesis. Adv Exp Med Biol 872 (2015), 353–380.
[9] Stulnig, T.M., Waldhausl, W., 11β-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes. Diabetologia 47 (2004), 1–11.
[10] Lutz, S.Z., Peter, A., Machicao, F., et al. Genetic variation in the 11β-hydroxysteroiddehydrogenase 1 gene determines NAFLD and visceral obesity. J Clin Endocrinol Metab, 2016 Oct 7 [Epub ahead of print].
[11] Bisschop, P.H., Dekker, M.J., Osterthun, W., et al. Expression of 11β-hydroxysteroid dehydrogenase type 1 in the human hypothalamus. J Neuroendocrinol 25 (2013), 425–432.
[12] Seckl, J.R., 11β-Hydroxysteroid dehydrogenase in the brain: a novel regulator of glucocorticoid action?. Front Neuroendocrinol 18 (1997), 49–99.
[13] Gray, G.A., White, C.I., Castellan, R.F., et al. Getting to the heart of glucocorticoid regeneration: 11β-HSD1 and the myocardium. J Mol Endocrinol, 2016 Aug 23 [Epub ahead of print].
[14] Terao, M., Katayama, I., Local cortisol/corticosterone activation in skin physiology and pathology. J Dermatol Sci 84 (2016), 11–16.
[15] Vitku, J., Starka, L., Bicikova, M., et al. Endocrine disruptors and other inhibitors of 11β-hydroxysteroid dehydrogenase 1 and 2: Tissue-specific consequences of enzyme inhibition. J Steroid Biochem Mol Biol 155 (2016), 207–216.
[16] Gogebakan, O., Andres, J., Biedasek, K., et al. Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11β-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids. Diabetes 61 (2012), 292–300.
[17] Bujalska, I.J., Kumar, S., Stewart, P.M., Does central obesity reflect «Cushing's disease of the omentum»?. Lancet 349 (1997), 1210–1213.
[18] Valsamakis, G., Anwar, A., Tomlinson, J.W., et al. 11β-hydroxysteroid dehydrogenase type. activity in lean and obese males with type. diabetes mellitus. J Clin Endocrinol Metab 89 (2004), 4755–4761.
[19] Woods, C.P., Corrigan, M., Gathercole, L., et al. Tissue specific regulation of glucocorticoids in severe obesity and the response to significant weight loss following bariatric surgery (BARICORT). J Clin Endocrinol Metab 100 (2015), 1434–1444.
[20] Abdallah, B.M., Beck-Nielsen, H., Gaster, M., Increased expression of 11β-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes. Eur J Clin Invest 35 (2005), 627–634.
[21] Inder, W.J., Obeyesekere, V.R., Alford, F.P., Jang, C., Skeletal muscle 11βHSD1 activity of nondiabetic subjects is unaltered in central obesity-associated insulin resistance. Horm Metab Res 43 (2011), 257–260.
[22] Li, S., Liao, Y., Wang, L., et al. Dysregulation of hypothalamo-pituitary-adrenocortical axis in overweight female diabetic subjects is associated with downregulation of corticosteroid receptors and 11β-HSD1 in the brain. Horm Metab Res 48 (2016), 178–184.
[23] Stimson, R.H., Andrew, R., McAvoy, N.C., et al. Increased whole-body and sustained liver cortisol regeneration by 11β-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition. Diabetes 60 (2011), 720–725.
[24] Stomby, A., Andrew, R., Walker, B.R., Olsson, T., Tissue-specific dysregulation of cortisol regeneration by 11βHSD1 in obesity: has it promised too much?. Diabetologia 57 (2014), 1100–1110.
[25] Wang, M., Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. Handb Exp Pharmacol(203), 2011, 127–146.
[26] Anagnostis, P., Katsiki, N., Adamidou, F., et al. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?. Metabolism 62 (2013), 21–33.
[27] Hawkins, M., Hunter, D.J., Kishore, P., et al. INCB013739, a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1), improves insulin sensitivity and lowers plasma cholesterol over 28 days in patients with type 2 diabetes mellitus (abstract). Diabetes 57:Suppl.1 (2008), A99–A100 [Abstract].
[28] Rosenstock, J., Banarer, S., Fonseca, V.A., et al. INCB1379-202 Principal Investigators The 11-p-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 33 (2010), 1516–1522.
[29] Wright, D.H., Stone, J.A., Crumley, T.M., et al. Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects. Br J Clin Pharmacol 76 (2013), 917–931.
[30] Feig, P.U., Shah, S., Hermanowski-Vosatka, A., et al. Effects of an 11 ß-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab 13 (2011), 498–504.
[31] Shah, S., Hermanowski-Vosatka, A., Gibson, K., et al. Efficacy and safety of the selective 11 ß-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. J Am Soc Hypertens 5 (2011), 166–176.
[32] Anderson, A., Walker, B.R., 11ß-HSD1 inhibitors for the treatment of type 2 diabetes and cardiovascular disease. Drugs 73 (2013), 1385–1393.
[33] Schnackenberg, C.G., Costell, M.H., Krosky, D.J., et al. Chronic inhibition of 11 ß-hydroxysteroid dehydrogenase type 1 activity decreases hypertension, insulin resistance, and hypertriglyceridemia in metabolic syndrome. Biomed Res Int, 2013, 2013, 427640.
[34] Scheen, A.J., Antidiabétiques oraux dans le traitement du diabète de type 2 : perspectives historique et médico-économique. Médecine des maladies Métaboliques 9 (2015), 186–197.
[35] Hughes, K.A., Manolopoulos, K.N., Iqbal, J., et al. Recycling between cortisol and cortisone in human splanchnic, subcutaneous adipose, and skeletal muscle tissues in vivo. Diabetes 61 (2012), 1357–1364.
[36] Morentin Gutierrez, P., Gyte, A., deSchoolmeester, J., et al. Continuous inhibition of 11β-hydroxysteroid dehydrogenase type I in adipose tissue leads to tachyphylaxis in humans and rats but not in mice. Br J Pharmacol 172 (2015), 4806–4816.
[37] Yuan, X., Li, H., Bai, H., et al. The 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against the insulin resistance and hepatic steatosis in db/db mice. Eur J Pharmacol 788 (2016), 140–151.
[38] Stefan, N., Ramsauer, M., Jordan, P., et al. Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2 (2014), 406–416.
[39] Luyckx, F.H., Lefebvre, P.J., Scheen, A.J., Nonalcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 26 (2000), 98–106.
[40] Scheen, A.J., Central nervous system: a conductor orchestrating metabolic regulations harmed by both hyperglycaemia and hypoglycaemia. Diabetes Metab 36:Suppl.3 (2010), S31–S38.
[41] Martocchia, A., Stefanelli, M., Falaschi, G.M., et al. Recent advances in the role of cortisol and metabolic syndrome in age-related degenerative diseases. Aging Clin Exp Res 28 (2016), 17–23.
[42] Liu, W., Katz, D.A., Locke, C., et al. Clinical safety, pharmacokinetics, and pharmacodynamics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers and elderly adults. Clin Pharmacol Drug Dev 2 (2013), 133–151.
[43] Katz, D.A., Liu, W., Locke, C., et al. Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384. Transl Psychiatry, 3, 2013, e295.
[44] Marek, G.J., Katz, D.A., Meier, A., et al. Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease. Alzheimers Dementia 10:5 Suppl (2014), S364–S373.
[45] Scott, J.S., Goldberg, F.W., Turnbull, A.V., Medicinal chemistry of inhibitors of 11 ß-hydroxysteroid dehydrogenase type 1 (11 ß-HSD1). J Med Chem 57 (2014), 4466–4486.